Prevalence and risk factors of Hepatitis C among individuals presenting to HIV testing centers, Hawassa city, Southern Ethiopia

被引：12
作者：
Alemayehu A. [1 ]
Tassachew Y. [1 ]
Sisay Z. [2 ]
Shimelis T. [1 ]
机构：
[1] Department of Medical Laboratory Science, Hawassa University, Hawassa
[2] Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa
来源：
BMC Research Notes | / 4卷 / 1期
关键词：
co-; infection; hepatitis C virus; human immunodeficiency virus; Prevalence;
D O I：
10.1186/1756-0500-4-193
中图分类号：
学科分类号：
摘要：
Background: Hepatitis C virus (HCV), either alone or in combination with Human Immunodeficiency virus (HIV), constitutes a major public health concern. This study was conducted to describe the prevalence and risk factors for HCV infection in people with and without HIV infection. Methods. Blood samples and data on socio-demographic and risk factors for HCV infection were collected from consecutive 400 HIV- positive and 400 HIV- negative individuals attending HIV testing centers in Hawassa city, from October to December, 2008. All sera were tested for antibody to HCV infection (anti-HCV) using enzyme linked immunosorbent assay (ELISA). Sera positive for anti-HCV were further tested for viral ribonucleic acid (RNA) levels using real-time polymerase chain reaction. Results: The rate of anti-HCV positivity was 10.5% in the HIV- infected individuals compared with 6% in the HIV negative group (p = 0.002). HCV-RNA was detected in 9.1% of anti-HCV positive samples and rates were comparable between HIV- infected and HIV- non-infected individuals. There was no significant difference in odds of HCV infection in participants with and without HCV risk factors in either HIV sero-group. Conclusion: HIV infected individuals had significantly higher rate of anti-HCV although most of them showed no evidence of viraemia. Hence, while priority should be given for HIV infected patients, testing those with anti-HCV for HCV-RNA remains important. © 2011 Shimelis et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 20 条
  • [1] Lavanchy D., The global burden of hepatitis C, Liver Int, 29, pp. 74-81, (2009)
  • [2] Alter M.J., Epidemiology of hepatitis C virus infection, World Journal of Gastroenterology, 13, 17, pp. 2436-2441, (2007)
  • [3] Liang T.J., Rehermann B., Seeff L.B., Hoofnagle J.H., Pathogenesis, natural history, treatment, and prevention of hepatitis C, Annals of Internal Medicine, 132, 4, pp. 296-305, (2000)
  • [4] Hoofnagle J.H., The national commission on digestive diseases, Hepatology, 44, 1, (2006)
  • [5] Thimme R., Spangenberg H., Blum H., Hepatitis B or hepatitis C and human immunodeficiency virus infection, J Hepatol, 42, pp. 37-44, (2005)
  • [6] Frommel D., Tekle-Haimanot R., Berhe N., Aussel L., Verdier M., Preux P., Denis F., A survey of antibodies to hepatitis C virus in Ethiopia, Am J Trop Hyg, 49, pp. 435-439, (1993)
  • [7] Ayele W., Nokes D.J., Abebe A., Messele T., Dejene A., Enquselassie F., Rinke De Wit T.F., Fontanet A.L., Higher prevalence of anti-HCV antibodies among HIV-positive compared to HIV-negative inhabitants of Addis Ababa, Ethiopia, Journal of Medical Virology, 68, 1, pp. 12-17, (2002)
  • [8] Toro C., Simon A., Amor A., Jimenez V., Rios P., Soriano V., HCV Seronegative Infections in HIV Patients with Profound Immunosuppresion, (2008)
  • [9] Buxton A.J., Yu A., Kim H.P., Spinelli J.J., Kuo M., Alvarez M., Gilbert M., Krajden M., HCV co-infection in HIV positive population in British Columbia, Canada, BMC Public Health, 10, pp. 225-236, (2010)
  • [10] Rockstroh J.K., Mocroft A., Soriano V., Tural C., Losso M.H., Horban A., Kirk O., Phillips A., Ledergerber B., Lundgren J., Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy, Journal of Infectious Diseases, 192, 6, pp. 992-1002, (2005)
12